Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.
BACKGROUND
The 21-kDa Vaccinia virus VH1-related (VHR) dual-specific protein phosphatase (encoded by the DUSP3 gene) plays a critical role in cell cycle progression and is itself regulated during the cell cycle. We have previously demonstrated using RNA interference that cells lacking VHR arrest in the G1 and G2 phases of the cell cycle and show signs of beginning of cell senescence.


METHODS
In this report, we evaluated successfully the expression levels of VHR protein in 62 hysterectomy or conization specimens showing the various (pre) neoplastic cervical epithelial lesions and 35 additional cases of hysterectomy performed for non-cervical pathologies, from patients under 50 years of age. We used a tissue microarray and IHC technique to evaluate the expression of the VHR phosphatase. Immunofluorescence staining under confocal microscopy, Western blotting and RT-PCR methods were used to investigate the localization and expression levels of VHR.


RESULTS
We report that VHR is upregulated in (pre) neoplastic lesions (squamous intraepithelial lesions; SILs) of the uterine cervix mainly in high grade SIL (H-SIL) compared to normal exocervix. In the invasive cancer, VHR is also highly expressed with nuclear localization in the majority of cells compared to normal tissue where VHR is always in the cytoplasm. We also report that this phosphatase is highly expressed in several cervix cancer cell lines such as HeLa, SiHa, CaSki, C33 and HT3 compared to primary keratinocytes. The immunofluorescence technique under confocal microscopy shows that VHR has a cytoplasmic localization in primary keratinocytes, while it localizes in both cytoplasm and nucleus of the cancer cell lines investigated. We report that the up-regulation of this phosphatase is mainly due to its post-translational stabilization in the cancer cell lines compared to primary keratinocytes rather than increases in the transcription of DUSP3 locus.


CONCLUSIONS
These results together suggest that VHR can be considered as a new marker for cancer progression in cervix carcinoma and potential new target for anticancer therapy.
Henkens
Rachel
R
Immunology and Infectious Diseases Unit, GIGA-R, Liège University, Liège, Belgium. r.henkens@student.ulg.ac.be
Delvenne
Philippe
P
Arafa
Mohammad
M
Moutschen
Michel
M
Zeddou
Mustapha
M
Tautz
Lutz
L
Boniver
Jacques
J
Mustelin
Tomas
T
Rahmouni
Souad
S
D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000201:enzymology; D054640:Dual Specificity Phosphatase 3 / Q000096:biosynthesis*; D004790:Enzyme Induction; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007044:Hysterectomy; D015603:Keratinocytes / Q000201:enzymology / Q000473:pathology; D018613:Microscopy, Confocal; D020411:Oligonucleotide Array Sequence Analysis; D013223:Statistics as Topic; D002583:Uterine Cervical Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D002578:Uterine Cervical Dysplasia / Q000201:enzymology* / Q000473:pathology / Q000601:surgery
C517025:DUSP3 protein, human; D054640:Dual Specificity Phosphatase 3